Van Hauwermeiren Timothy 4

What Happened

• Timothy Van Hauwermeiren, a director of Lexeo Therapeutics, reported receipt of a 35,000-share equity award (derivative) on June 25, 2026. The filing lists an acquisition price of $0.00, indicating a grant/award rather than an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-25, grant reported at $0.00 per share (code A — grant/award).
• Shares acquired: 35,000 underlying shares (derivative award/option).
• Shares owned after transaction: Not disclosed in the Form 4.
• Vesting/conditions (footnote): 100% of the shares underlying the option vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to continuous service.
• Filing timeliness: Form 4 filed 2026-06-29; no late filing indicated.

Context

• This was a compensation award (derivative/option underlying shares), not an open-market purchase. The award will only convert to exercisable shares per the stated vesting condition; it does not represent an immediate cash outlay or sale. Such grants are common for directors as part of compensation and do not, by themselves, signal a personal market purchase or sale.